<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01858740</url>
  </required_header>
  <id_info>
    <org_study_id>2660.00</org_study_id>
    <secondary_id>NCI-2013-00958</secondary_id>
    <secondary_id>2660</secondary_id>
    <secondary_id>2660.00</secondary_id>
    <secondary_id>K23CA154532</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT01858740</nct_id>
  </id_info>
  <brief_title>Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children</brief_title>
  <official_title>A Phase II Study of Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well T cell depleted donor peripheral blood stem cell
      transplant works in preventing graft-versus-host disease in younger patients with high risk
      hematologic malignancies. Giving chemotherapy and total-body irradiation before a donor
      peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop
      the patient's immune system from rejecting the donor's stem cells. When the healthy stem
      cells from a donor are infused into the patient they may help the patient's bone marrow make
      stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted
      cells from a donor can make an immune response against the body's normal cells. Removing a
      subset of the T cells from the donor cells before transplant may stop this from happening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Estimate the time to discontinuation of systemic immunosuppression in pediatric recipients
      of cluster of differentiation 45RA positive (CD45RA+) T cell-depleted peripheral blood stem
      cell transplant (PBSCT).

      II. Estimate the probability of graft failure in pediatric recipients of CD45RA+
      T-cell-depleted PBSCT.

      SECONDARY OBJECTIVES:

      I. Estimate and compare to an appropriate historical cohort the probability of chronic
      graft-versus-host disease (GVHD) (National Institutes of Health [NIH] criteria) requiring
      treatment with systemic pharmacological immunosuppression in pediatric patients who receive
      CD45RA+ T cell depleted PBSC.

      II. Estimate the probability of acute GVHD grade II-IV.

      III. Estimate the probability of steroid refractory acute GVHD.

      IV. Evaluate immune reconstitution.

      V. Estimate the probability of transplant-related mortality by day 100.

      VI. Estimate the probability of relapse.

      OUTLINE:

      CONDITIONING REGIMEN: Patients undergo total body irradiation (TBI) twice daily (BID) on days
      -10 to -7, receive thiotepa intravenously (IV) over 4 hours on days -6 and -5 and fludarabine
      phosphate IV over 30 minutes on days -6 to -2.

      TRANSPLANT: Patients undergo CD34+ enriched, CD45RA+ T cell-depleted allogeneic PBSCT on day
      0.

      POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV continuously or orally (PO)
      every 12 hours beginning on day -1 and continuing through day 50 with taper. Patients also
      receive methotrexate IV on days 1, 3, 6, and 11.

      After completion of study treatment, patients are followed up for up to 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 17, 2013</start_date>
  <completion_date type="Anticipated">January 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Graft failure defined as failure to reach an absolute neutrophil count (ANC) of &gt; 500/ul for 3 consecutive days or irreversible decrease in ANC to &lt; 100 after an established donor graft</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>A true probability of graft failure of 10% will be considered excessive. If there is sufficient evidence to suggest that the true probability of graft failure exceeds 10%, the study will be stopped.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to ANC of &gt; 1,000/uL</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to ANC of &gt; 500/uL</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to discontinuation of systemic immunosuppression</measure>
    <time_frame>Time from transplant to the final discontinuation of all systemic immune suppression assessed up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to platelet count &gt; 20,000/uL for 3 days without transfusion</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to platelet count &gt; 50,000/uL for 3 days without transfusion</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of chronic GHVD meeting NIH criteria and requiring systemic pharmacological immunosuppression</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of acute GVHD grade III-IV</measure>
    <time_frame>Up to day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of acute GVHD grades II-IV</measure>
    <time_frame>Up to day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of steroid refractory acute GVHD</measure>
    <time_frame>Up to day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse defined by the presence of malignant cells in marrow, peripheral blood, or extramedullary sites by histopathology</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant related mortality defined as mortality in any patient for whom there has not been a diagnosis of relapse</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of additional immune suppressive agents other than first line therapy</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Acute Biphenotypic Leukemia</condition>
  <condition>Acute Leukemia of Ambiguous Lineage</condition>
  <condition>Acute Undifferentiated Leukemia</condition>
  <condition>Adult Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Adult Acute Myeloid Leukemia in Remission</condition>
  <condition>Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Childhood Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Childhood Acute Myeloid Leukemia in Remission</condition>
  <condition>Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Myelodysplastic Syndrome With Excess Blasts-1</condition>
  <condition>Myelodysplastic Syndrome With Excess Blasts-2</condition>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Recurrent Childhood Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Childhood Acute Myeloid Leukemia</condition>
  <condition>Refractory Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Refractory Childhood Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (CD45RA+ T cell depleted PBSCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CONDITIONING REGIMEN: Patients undergo TBI BID on days -10 to -7, receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2.
TRANSPLANT: Patients undergo CD34+ enriched, CD45RA+ T cell-depleted allogeneic PBSCT on day 0.
POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV continuously or PO every 12 hours beginning on day -1 and continuing through day 50 with taper. Patients also receive methotrexate IV on days 1, 3, 6, and 11.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant</description>
    <arm_group_label>Treatment (CD45RA+ T cell depleted PBSCT)</arm_group_label>
    <other_name>allogeneic stem cell transplantation</other_name>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (CD45RA+ T cell depleted PBSCT)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (CD45RA+ T cell depleted PBSCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (CD45RA+ T cell depleted PBSCT)</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>CL 14377</other_name>
    <other_name>CL-14377</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emthexate</other_name>
    <other_name>Farmitrexat</other_name>
    <other_name>Fauldexato</other_name>
    <other_name>Folex</other_name>
    <other_name>Folex PFS</other_name>
    <other_name>Lantarel</other_name>
    <other_name>Ledertrexate</other_name>
    <other_name>Lumexon</other_name>
    <other_name>Maxtrex</other_name>
    <other_name>Medsatrexate</other_name>
    <other_name>Metex</other_name>
    <other_name>Methoblastin</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methotrexate Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
    <other_name>Metotrexato</other_name>
    <other_name>Metrotex</other_name>
    <other_name>Mexate</other_name>
    <other_name>Mexate-AQ</other_name>
    <other_name>MTX</other_name>
    <other_name>Novatrex</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Texate</other_name>
    <other_name>Tremetex</other_name>
    <other_name>Trexeron</other_name>
    <other_name>Trixilem</other_name>
    <other_name>WR-19039</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant</description>
    <arm_group_label>Treatment (CD45RA+ T cell depleted PBSCT)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplant</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>T Cell-Depleted Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant</description>
    <arm_group_label>Treatment (CD45RA+ T cell depleted PBSCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Treatment (CD45RA+ T cell depleted PBSCT)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (CD45RA+ T cell depleted PBSCT)</arm_group_label>
    <other_name>1,1',1''-Phosphinothioylidynetrisaziridine</other_name>
    <other_name>Girostan</other_name>
    <other_name>N,N', N''-Triethylenethiophosphoramide</other_name>
    <other_name>Oncotiotepa</other_name>
    <other_name>STEPA</other_name>
    <other_name>Tepadina</other_name>
    <other_name>TESPA</other_name>
    <other_name>Tespamin</other_name>
    <other_name>Tespamine</other_name>
    <other_name>Thio-Tepa</other_name>
    <other_name>Thiofosfamide</other_name>
    <other_name>Thiofozil</other_name>
    <other_name>Thiophosphamide</other_name>
    <other_name>Thiophosphoramide</other_name>
    <other_name>Thiotef</other_name>
    <other_name>Tifosyl</other_name>
    <other_name>TIO TEF</other_name>
    <other_name>Tio-tef</other_name>
    <other_name>Triethylene Thiophosphoramide</other_name>
    <other_name>Triethylenethiophosphoramide</other_name>
    <other_name>Tris(1-aziridinyl)phosphine sulfide</other_name>
    <other_name>TSPA</other_name>
    <other_name>WR 45312</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Treatment (CD45RA+ T cell depleted PBSCT)</arm_group_label>
    <other_name>TOTAL BODY IRRADIATION</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are considered appropriate candidates for allogeneic hematopoietic stem
             cell transplantation and have one of the following diagnoses:

               -  Acute lymphocytic leukemia in first or subsequent remission

               -  Acute myeloid leukemia in first or subsequent remission

               -  Acute lymphocytic leukemia in relapse or primary refractory disease with a
                  circulating blast count of no more than 10,000/mm^3

               -  Acute myeloid leukemia in relapse or primary refractory disease with a
                  circulating blast count of no more than 10,000/mm^3

               -  Refractory anemia with excess blasts (RAEB-1 and RAEB-2)

               -  Chronic myelogenous leukemia with a history of accelerated phase or blast crisis

               -  Other acute leukemia (including but not limited to 'biphenotypic',
                  'undifferentiated' or 'ambiguous lineage' acute leukemia)

          -  Patient with a human leukocyte antigen (HLA)-identical (HLA-A, B, C, and ribonucleic
             acid [RNA] binding motif protein 45 [DRB1] molecularly matched) unrelated donor or
             related donor capable of donating PBSC

          -  DONOR: HLA-matched unrelated donors (HLA-A, B, C, and DRB1 matched based on
             high-resolution typing) capable and willing to donate PBSC

          -  DONOR: HLA-matched related donors &gt;= 18 years and capable and willing to donate PBSC

        Exclusion Criteria:

          -  Patients with central nervous system (CNS) involvement refractory to intrathecal
             chemotherapy and/or standard cranial-spinal radiation

          -  Patients on other experimental protocols for prevention of acute GVHD

          -  Patients who weigh &gt;= 70 kg must be discussed with the principal investigator prior to
             enrolling on the protocol

          -  Patients who are human immunodeficiency virus positive (HIV+)

          -  Patients with uncontrolled infections for whom myeloablative hematopoietic stem cell
             transplant (HCT) is considered contraindicated by the consulting infectious disease
             physician (upper respiratory tract viral infection does not constitute an uncontrolled
             infection in this context)

          -  Creatinine &gt; 1.5 mg/dl

          -  Cardiac ejection fraction &lt; 45%

          -  Patients who can perform pulmonary function tests will be excluded if they have a
             diffusing capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin)
             of &lt; 60% predicted; patients who are unable to perform pulmonary function tests (for
             example, due to young age and/or developmental status) will be excluded if the oxygen
             (O2) saturation is &lt; 92% on room air

          -  Patients who have liver function test (LFTs) (including total bilirubin, aspartate
             aminotransferase [AST] and alanine aminotransferase [ALT]) &gt;= twice the upper limit of
             normal should be evaluated by a gastrointestinal (GI) physician unless there is a
             clear precipitating factor (such as an azole, methotrexate, Bactrim or another drug);
             if the GI physician considers that HCT on protocol 2660 is contraindicated for that
             patient the patient will be excluded from the protocol; patients with Gilbert's
             syndrome and no other known liver function abnormality and patients with reversible
             drug-related transaminitis do not necessarily require GI consultation and may be
             included on the protocol

          -  Patients with a life expectancy &lt; 3 months from co-existing disease other than the
             leukemia or RAEB

          -  Patients who are pregnant or breast-feeding

          -  Fertile patients of child bearing age unwilling to use contraception during and for 12
             months post-transplant

          -  Patients with a significant other medical conditions that would make them unsuitable
             for transplant

          -  Patients with a known hypersensitivity to tacrolimus

          -  DONOR: Donors who are HIV-1, HIV-2, human T-lymphotropic virus (HTLV)-1, HTLV-2
             seropositive or with active hepatitis B or hepatitis C virus infection

          -  DONOR: Donors who fail eligibility requirements for donation of cells or tissue per
             section 21 Code of Federal Regulations (CFR) 1271 for donation of a HCT/product (P)
             will be excluded unless use of the cells complies with 21 CFR 1271.65(b)(iii) (urgent
             medical need) or with 21 CFR 1271.65(b)(i) (allogeneic use in a first-degree or
             second-degree relative)

          -  DONOR: Unrelated donors donating outside of the United States of America (USA) or
             Germany
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Bleakley</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2013</study_first_submitted>
  <study_first_submitted_qc>May 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2013</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Accelerated Phase</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
    <mesh_term>Anemia, Refractory, with Excess of Blasts</mesh_term>
    <mesh_term>Leukemia, Biphenotypic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

